Skip to main content

Table 1 Correlation between LC3/ALDH1 coexpression and clinicopathological profiles

From: Blockade of autophagy reduces pancreatic cancer stem cell activity and potentiates the tumoricidal effect of gemcitabine

Characteristic Low LC3/ALDH1 High LC3/ALDH1 P
Age, median (range) 67 (38–85) 64 (37–85)  
Sex    
  Male 37 (68.5) 23 (59.0) 0.342
  Female 17 (31.5) 16 (41.0)  
Tumor location    
  Head 28 (51.9) 29 (74.4) 0.177
  Neck 5 (9.3) 2 (5.1)  
  Body/tail 12 (22.2) 4 (10.3)  
  Uncinate process 9 (16.7) 4 (10.3)  
Tumor size    
   < 3 cm 30 (55.6) 22 (56.4) 0.935
   ≥ 3 cm 24 (44.4) 17 (43.6)  
Lymph nodes    
  Negative 30 (55.6) 16 (41.0) 0.167
  Positive 24 (44.4) 23 (59.0)  
Margin status    
  R0 41 (75.9) 25 (64.1) 0.462
  R1 11 (20.4) 12 (30.8)  
  R2 2 (3.7) 2 (5.1)  
Tumor grade    
  Poorly diff. 11 (20.4) 6 (15.4) 0.345
  Moderate diff. 25 (46.3) 24 (61.5)  
  Well diff. 18 (33.3) 9 (23.1)  
Stage    
  I 10 (18.5) 1 (2.6) 0.097
  II 40 (74.1) 36 (92.3)  
  III 3 (5.6) 1 (2.6)  
  IV 1 (1.9) 1 (2.6)  
CA19-9    
   < 37U/ml 12 (22.2) 8 (20.5) 0.843
   ≥ 37U/ml 42 (77.8) 31 (79.5)  
Adjuvant therapy    
  Yes 26 (48.1) 11 (28.2) 0.053
  No 28 (51.9) 28 (71.8)  
Diabetes mellitus    
  Yes 18 (33.3) 11 (28.2) 0.598
  No 36 (66.7) 28 (71.8)  
Survival    
  Yes 35 (64.8) 12 (30.8) 0.001
  No 19 (35.2) 27 (69.2)  
Recurrence    
  Yes 26 (48.1) 35 (89.7) 0.000
  No 28 (51.9) 4 (10.3)  
  1. The bold value indicates P < 0.05